STOCK TITAN

Scribe Therapeutics Q3 revenue falls to $1.64M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. (SCTX) reported third-quarter 2026 collaboration revenue of $1.636 million, compared with $20.113 million in the year-earlier quarter, and a net loss of $9.863 million ($0.68 per basic and diluted share), versus net income of $1.472 million. Research and development expense was $8.259 million versus $14.421 million; general and administrative expense was $4.239 million versus $3.531 million. Cash, cash equivalents and marketable securities were $174.230 million at September 30, 2026. Under its current operating plan, Scribe believes these funds will cover operating expenses and capital expenditures into the first half of 2029.

The Phase 1 trial of STX-1150 is ongoing, with initial data expected in the first half of 2027. In non-human primates, a single 0.75 mg/kg administration produced LDL-C reductions greater than 50% sustained for two years, with liver enzyme profiles comparable to saline controls; STX-1200 surrogates achieved greater than 95% Lp(a) reduction. Scribe also expanded its multi-year Sanofi collaboration to include its ELXR epigenetic silencing technology.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway is expected into the first half of 2029.

Negative

  • Moderate pointCollaboration revenue was $1.636 million, down from $20.113 million in Q3 2025.
  • Moderate pointQuarterly net result shifted from $1.472 million income to a $9.863 million loss.

Filing Explained

Scribe reports its IPO, the underwriters’ full option exercise and concurrent Sanofi private placement raised approximately $155.5 million gross and $140.2 million net. Cash, cash equivalents and investments increased from $43.0 million at June 30, 2026 to $174.2 million at September 30, 2026, adding completed financing to company resources.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Collaboration revenue $1.636 million Three months ended September 30, 2026; $20.113 million in the same period of 2025.
Net loss $9.863 million Three months ended September 30, 2026; compared with net income of $1.472 million in the same period of 2025.
Loss per basic and diluted share $0.68 per share Third quarter of 2026.
Cash, cash equivalents and marketable securities $174.230 million As of September 30, 2026.
Expected funding runway Into the first half of 2029 Based on the company's current operating plan.
Research and development expenses $8.259 million Three months ended September 30, 2026; compared with $14.421 million in the same period of 2025.
STX-1150 LDL-C reduction Greater than 50% In non-human primates after a single 0.75 mg/kg administration, sustained for two years.
STX-1200 Lp(a) reduction Greater than 95% Achieved by STX-1200 surrogates in non-human primates in preclinical studies.
Epigenetic Long-term X Repressor (ELXR) technical
"utilizes Scribe’s Epigenetic Long-term X Repressor (ELXR) technology"
low-density lipoprotein cholesterol (LDL-C) medical
"therapy for low-density lipoprotein cholesterol (LDL-C) lowering"
Low-density lipoprotein cholesterol (LDL-C) is the portion of blood cholesterol carried by particles that deliver cholesterol to arteries; think of LDL-C as delivery trucks that can leave sticky deposits in vessel walls. Investors care because high LDL-C levels drive demand for tests, medications, medical devices and preventive care, influence clinical trial outcomes and regulatory decisions, and help determine future healthcare spending and revenue for companies in the cardiovascular sector.
PCSK9 medical
"to silence PCSK9, a genetically and clinically validated target"
PCSK9 is a protein made in the body that controls how many 'bad' cholesterol receptors remain on liver cells, acting like a gatekeeper that determines how much LDL cholesterol is cleared from the blood. It matters to investors because medicines that block PCSK9 can sharply lower cholesterol and reduce heart risk, creating large markets, regulatory milestones, and patent/value drivers for drug developers and healthcare portfolios.
lipoprotein(a) (Lp(a)) medical
"designed to lower lipoprotein(a) (Lp(a))"
atherosclerotic cardiovascular disease (ASCVD) medical
"increased risk of atherosclerotic cardiovascular disease (ASCVD)"
Atherosclerotic cardiovascular disease (ASCVD) is the long-term narrowing and hardening of arteries caused by buildup of fatty plaques, which can block blood flow and lead to heart attacks, strokes or limb problems—think of arteries as pipes that become clogged over time. It matters to investors because ASCVD drives demand for drugs, medical devices, diagnostic tests and long-term care, influences healthcare costs and regulatory scrutiny, and affects the market potential and revenue forecasts for companies in healthcare and insurance.
X-Editor (XE) technical
"utilizing X-Editor (XE), Scribe’s highly engineered gene editing technology"
Collaboration revenue $1.636 million $20.113 million in the third quarter of 2025
Research and development expenses $8.259 million $14.421 million in the third quarter of 2025
General and administrative expenses $4.239 million $3.531 million in the third quarter of 2025
Net loss $9.863 million Net income of $1.472 million in the third quarter of 2025
Loss per basic and diluted share $0.68 per share
Cash, cash equivalents and marketable securities $174.230 million $43.0 million as of June 30, 2026
Guidance

Based on its current operating plan, Scribe believes cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into the first half of 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were SCTX's third-quarter 2026 financial results?

Collaboration revenue was $1.636 million and net loss was $9.863 million, or $0.68 per basic and diluted share. In the same quarter of 2025, collaboration revenue was $20.113 million and the company reported net income of $1.472 million.

When does Scribe expect initial STX-1150 Phase 1 data?

Scribe anticipates initial clinical data in the first half of 2027, including safety, tolerability and LDL-C lowering activity from the single ascending dose portion of the trial.

What did Scribe report about STX-1150 in non-human primates?

A single 0.75 mg/kg administration demonstrated LDL-C reductions greater than 50% sustained for two years, with liver enzyme profiles comparable to saline controls. In an additional study, re-dosing enabled progressively greater LDL-C lowering while maintaining tolerability.

What changed in Scribe's Sanofi collaboration?

The expanded multi-year research collaboration gives Sanofi access to Scribe’s ELXR epigenetic silencing technology in addition to its XE gene-editing technology, and extends Sanofi’s target-selection nomination period under the license agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000185392100018539212026-11-122026-11-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

Scribe Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-43409

82-2157847

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1150 Marina Village Parkway

 

Alameda, California

 

94501

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 510 626-8587

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, $0.001 par value per share

 

SCTX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 2.02 Results of Operations and Financial Condition.

On November 12, 2026, Scribe Therapeutics Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026 and provided a business update. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit number

Description

99.1

Earnings Press Release Issued by Scribe Therapeutics Inc on November 12, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 12, 2026

 

By:

/s/ Benjamin L. Oakes

 

 

 

Benjamin L. Oakes, Ph.D.

 

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 


img260493329_0.gif

 

 

 

Scribe Therapeutics Reports Third Quarter 2026 Financial Results

and Recent Corporate Highlights

 

Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400

 

Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the Company’s epigenetic silencing therapy for LDL-C lowering, with initial clinical data expected in the first half of 2027

 

Expanded strategic collaboration with Sanofi, providing access to the Company’s ELXR silencing technology and further validating its platform innovation


Reinforced leadership in genetic medicines through presentations and a new publication highlighting advances across the Company’s cardiovascular pipeline and proprietary epigenetic silencing and gene-editing technologies

 

Cash, cash equivalents, and marketable securities of $174.2 million as of September 30, 2026, provide funding into the first half of 2029

 

ALAMEDA, Calif., November 12, 2026 – Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate and pipeline updates.

 

During the third quarter, Scribe continued to build on the momentum generated by its successful initial public offering. The Company completed an upsized IPO, welcomed leading public healthcare investors to its shareholder base, and broadened analyst coverage, positioning the Company to execute against its long-term vision of developing durable genetic medicines for highly prevalent cardiometabolic diseases.

 

“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients," said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics.
 

 

Pipeline Highlights

STX-1150: In vivo epigenetic silencing therapy for low-density lipoprotein cholesterol (LDL-C) lowering in ongoing Phase 1 clinical trial

•
STX-1150 utilizes Scribe’s Epigenetic Long-term X Repressor (ELXR) technology to silence PCSK9, a genetically and clinically validated target for LDL-C lowering.

 

 

 


 

•
STX-1150 is designed to address a major limitation of current LDL-C lowering approaches and is positioned to recapitulate the cardioprotective effects of human genetics.
•
Current LDL-C lowering therapies are limited by poor persistence and adherence, with studies showing that 50% to 70% of patients discontinue treatment within one year.
•
STX-1150 is designed to overcome these challenges by providing potent, ultra-long-lasting LDL-C reduction.
•
STX-1150 aims to mimic the protective cardiovascular profile observed in individuals with naturally occurring PCSK9 loss-of-function variants, who have been reported to have 28% lower mean LDL-C levels and up to 88% lower coronary heart disease risk. By recapitulating the effects of this naturally occurring protection, STX-1150 has the potential to shift LDL-C management from burdensome chronic treatment to long-term prevention.

 

•
Presented late-breaking data at the American Heart Association (AHA) Scientific Sessions 2026 meeting supporting STX-1150 for ultra-long-lasting LDL-C lowering after a single dose without permanently altering DNA.
•
A single administration at a therapeutically relevant dose of 0.75 mg/kg demonstrated durable LDL-C reductions of greater than 50%, sustained for two years, with liver enzyme profiles comparable to saline controls in non-human primates (NHP).
•
In an additional NHP study, re-dosing of STX-1150 enabled progressively greater LDL-C lowering while maintaining tolerability.

 

•
First-in-human Phase 1 clinical trial of STX-1150, initiated in mid-2026, is ongoing. Clinical data expected in the first half of 2027.
•
The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of STX-1150 in adults with elevated low-density lipoprotein cholesterol and increased risk of atherosclerotic cardiovascular disease (ASCVD).
•
Scribe anticipates reporting initial clinical data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose portion of the STX-1150 Phase 1 trial in the first half of 2027.

 

STX-1200: In vivo gene editing designed to provide curative lowering for patients with genetically elevated Lp(a)

•
Presented data at the AHA Scientific Sessions 2026 meeting highlighting STX-1200, which targets LPA utilizing X-Editor (XE), Scribe’s highly engineered gene editing technology.
•
STX-1200 is designed to lower lipoprotein(a) (Lp(a)) in patients with genetically elevated Lp(a) and associated ASCVD risk. In preclinical studies, STX-1200 surrogates achieved greater than 95% Lp(a) reduction in NHPs.
 

Corporate Highlights

•
Nasdaq listing: The Company’s common stock began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol “SCTX.” Scribe upsized its initial public offering and priced at the high end of the range. The Company also completed a concurrent private placement to Sanofi at the IPO price.
 
•
Approximately $155.5 million in aggregate gross proceeds: Capital raised from the IPO, the full exercise of the underwriters’ option, and the concurrent private placement totaled $155.5 million before underwriting discounts, commissions, and offering expenses.
 
•
Funding into the first half of 2029: Based on Scribe’s current operating plan, the Company believes its cash, cash equivalents, and marketable securities will be sufficient to fund its

 

 

 


 

operating expenses and capital expenditure requirements into the first half of 2029.
 
•
Expanded strategic collaboration with Sanofi to include Scribe’s ELXR epigenetic silencing technology: Scribe expanded its multi-year research collaboration with Sanofi, providing Sanofi access to Scribe’s proprietary ELXR epigenetic silencing technology in addition to its XE gene-editing technology and extending Sanofi’s nomination period for target selection under the license agreement.

Platform and Scientific Leadership

 

•
Presented advances in ELXR epigenetic silencing technology demonstrating improvements in potency and specificity.
•
At the European Society of Gene and Cell Therapy (ESGCT) Congress, Scribe presented findings demonstrating a novel approach to epigenetic silencing termed “sequential proofreading” that reduces unintended DNA methylation by 10-fold and enhances potency by at least 4-fold.
•
These advances highlight ELXR’s differentiated potency and precision and underpin the Company's lead asset STX-1150, currently in the clinic for LDL-C lowering.
•
New data highlight advances in industry-leading genome editing potency and specificity of the Company’s engineered XE gene-editing technology.
•
The Company’s comprehensive and iterative molecular engineering approach transformed CRISPR-CasX, a naturally occurring bacterial immune system, into its highly engineered XE gene-editing technology for therapeutic development. This foundational work underpins the Company’s STX-1200 and STX-1400 programs and has contributed to the development of its clinical-stage STX-1150 program, demonstrating the broader applicability of Scribe’s engineered platforms for cardiovascular disease.
•
The engineered XE technology exhibited >100-fold improvements in editing activity compared with naturally occurring CasX and demonstrated its ability to potently edit genes in vivo across muscle, eye, liver, and brain tissue.
•
XE demonstrated the potential for a broader therapeutic window by achieving saturating editing across two distinct genomic targets in NHP liver, with no detectable off-target editing in primary human liver cells at 10-fold supersaturating doses.
•
These findings demonstrate that XE is more potent at lower doses than comparable preclinical data from Cas9-based therapies that are now in clinical testing.
•
A manuscript has been submitted to bioRxiv and will be available in the Publications section of the Company’s website once posted.

Third Quarter 2026 Financial Results

 

•
Cash position: Cash, cash equivalents, and marketable securities were $174.2 million as of September 30, 2026, compared to $43.0 million as of June 30, 2026. The increase was primarily driven by approximately $140.2 million of net proceeds from the July 2026 IPO and concurrent private placement, partially offset by cash used in operations. Cash, cash equivalents, and marketable securities as of September 30, 2026, are expected to provide funding into the first half of 2029.
•
Collaboration revenue: For the three months ended September 30, 2026, collaboration revenue totaled $1.6 million, compared to $1.9 million for the three months ended June 30, 2026. The decrease was primarily attributable to lower revenue recognized under the Eli Lilly collaboration due to lower reimbursable research and development activities incurred in the period.

 

 

 


 

•
Research and development expenses: For the three months ended September 30, 2026, research and development expenses totaled $8.3 million, compared to $8.8 million for the three months ended June 30, 2026. The decrease was primarily attributable to lower employee-related and external research and development expenses and the recognition of grant funding from the California Institute for Regenerative Medicine (CIRM) as an offset to research and development expenses.
•
General and administrative expenses: For the three months ended September 30, 2026, general and administrative expenses totaled $4.2 million, compared to $2.5 million for the three months ended June 30, 2026. The increase was primarily attributable to higher stock-based compensation expenseand increased professional services fees and other costs associated with operating as a public company.
•
Net loss: For the three months ended September 30, 2026, net loss was $9.9 million, or $0.68 per basic and diluted share, compared to a net loss of $6.5 million for the three months ended June 30, 2026.

 

 

About Scribe Therapeutics Inc.

Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit
www.scribetx.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe’s strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe’s product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, STX-1400 and other programs; the expected use and benefits of CIRM funding; and Scribe’s expected cash runway and financial position are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
 

Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those described under the heading “Risk Factors” in Scribe’s filings with the U.S. Securities and Exchange Commission, including its final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to

 

 

 


 

update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events.

 

Investor Contact:

Investor Relations, Scribe Therapeutics

ir@scribetx.com

 

Media Contact:

Thermal for Scribe Therapeutics

media@scribetx.com

 

SCRIBE THERAPEUTICS INC.

Statement of Operations

(in thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Collaboration revenue

 

$

 

1,636

 

 

$

 

20,113

 

 

$

 

5,787

 

 

$

 

42,136

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

 

8,259

 

 

 

 

14,421

 

 

 

 

28,386

 

 

 

 

44,297

 

General and administrative

 

 

 

4,239

 

 

 

 

3,531

 

 

 

 

10,084

 

 

 

 

12,863

 

Total operating expenses

 

 

 

12,498

 

 

 

 

17,952

 

 

 

 

38,470

 

 

 

 

57,160

 

Loss from operations

 

 

 

(10,862

)

 

 

 

2,161

 

 

 

 

(32,683

)

 

 

 

(15,024

)

Interest income and other income, net

 

 

 

1,230

 

 

 

 

772

 

 

 

 

2,128

 

 

 

 

2,716

 

Interest expense

 

 

 

—

 

 

 

 

(598

)

 

 

 

(875

)

 

 

 

(1,795

)

Change in fair value of Convertible Note

 

 

 

—

 

 

 

 

(539

)

 

 

 

(1,585

)

 

 

 

1,543

 

Net loss before provision for income taxes

 

 

 

(9,632

)

 

 

 

1,796

 

 

 

 

(33,015

)

 

 

 

(12,560

)

(Provision for) / benefit from income tax

 

 

 

(231

)

 

 

 

(324

)

 

 

 

(672

)

 

 

 

703

 

Net loss

 

$

 

(9,863

)

 

$

 

1,472

 

 

$

 

(33,687

)

 

$

 

(11,857

)

 

 

 

 

 

 

SCRIBE THERAPEUTICS INC.

Selected Balance Sheet Items

(in thousands, except share and per share data)

(Unaudited)

 

 

September 30,

 

 

December 31,

 

 

2026

 

 

2025

 

 

 

 

(in thousands)

 

Cash, cash equivalents and investments

 

$

 

174,230

 

 

$

 

57,963

 

Total Assets

 

 

 

187,930

 

 

 

 

78,219

 

Total Liabilities

 

 

 

62,760

 

 

 

 

101,282

 

Total stockholders' equity / (deficit)

 

$

 

125,170

 

 

$

 

(143,419

)

 

 

 

 

 

 


Filing Exhibits & Attachments

2 documents

Keep reading